These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 23063887)

  • 1. Pharmacosynthetics: Reimagining the pharmacogenetic approach.
    Farrell MS; Roth BL
    Brain Res; 2013 May; 1511():6-20. PubMed ID: 23063887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optogenetics and pharmacogenetics: principles and applications.
    Jiang J; Cui H; Rahmouni K
    Am J Physiol Regul Integr Comp Physiol; 2017 Dec; 313(6):R633-R645. PubMed ID: 28794102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G protein-coupled receptor pharmacogenetics.
    Thompson MD; Siminovitch KA; Cole DE
    Methods Mol Biol; 2008; 448():139-85. PubMed ID: 18370234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The G protein-coupled receptors: pharmacogenetics and disease.
    Thompson MD; Burnham WM; Cole DE
    Crit Rev Clin Lab Sci; 2005; 42(4):311-92. PubMed ID: 16281738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug receptor/effector polymorphisms and pharmacogenetics: current status and challenges.
    Johnson JA; Lima JJ
    Pharmacogenetics; 2003 Sep; 13(9):525-34. PubMed ID: 12972951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in optogenetics and pharmacogenetics.
    Aston-Jones G; Deisseroth K
    Brain Res; 2013 May; 1511():1-5. PubMed ID: 23422677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics of the G protein-coupled receptors.
    Thompson MD; Cole DE; Capra V; Siminovitch KA; Rovati GE; Burnham WM; Rana BK
    Methods Mol Biol; 2014; 1175():189-242. PubMed ID: 25150871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics of G protein-coupled receptor signaling: insights from health and disease.
    Thompson MD; Cole DE; Jose PA
    Methods Mol Biol; 2008; 448():77-107. PubMed ID: 18370232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.
    Rushmore TH; Kong AN
    Curr Drug Metab; 2002 Oct; 3(5):481-90. PubMed ID: 12369894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p90 Ribosomal S6 kinase 2, a novel GPCR kinase, is required for growth factor-mediated attenuation of GPCR signaling.
    Strachan RT; Allen JA; Sheffler DJ; Roth BL
    Biochemistry; 2010 Mar; 49(12):2657-71. PubMed ID: 20136148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered GPCRs as tools to modulate signal transduction.
    Pei Y; Rogan SC; Yan F; Roth BL
    Physiology (Bethesda); 2008 Dec; 23():313-21. PubMed ID: 19074739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity.
    Smit MJ; Vischer HF; Bakker RA; Jongejan A; Timmerman H; Pardo L; Leurs R
    Annu Rev Pharmacol Toxicol; 2007; 47():53-87. PubMed ID: 17029567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemogenetics a robust approach to pharmacology and gene therapy.
    Keifer O; Kambara K; Lau A; Makinson S; Bertrand D
    Biochem Pharmacol; 2020 May; 175():113889. PubMed ID: 32119836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Directed molecular evolution of DREADDs: a generic approach to creating next-generation RASSLs.
    Dong S; Rogan SC; Roth BL
    Nat Protoc; 2010 Mar; 5(3):561-73. PubMed ID: 20203671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DREADD: a chemogenetic GPCR signaling platform.
    Zhu H; Roth BL
    Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25522378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered G-protein Coupled Receptors are Powerful Tools to Investigate Biological Processes and Behaviors.
    Nichols CD; Roth BL
    Front Mol Neurosci; 2009; 2():16. PubMed ID: 19893765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G protein-coupled receptors disrupted in human genetic disease.
    Thompson MD; Percy ME; McIntyre Burnham W; Cole DE
    Methods Mol Biol; 2008; 448():109-37. PubMed ID: 18370233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.
    Urban DJ; Roth BL
    Annu Rev Pharmacol Toxicol; 2015; 55():399-417. PubMed ID: 25292433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Strategies for Neuropathic Pain: Potential Application of Pharmacosynthetics and Optogenetics.
    Lee GH; Kim SS
    Mediators Inflamm; 2016; 2016():5808215. PubMed ID: 26884648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering GPCR signaling pathways with RASSLs.
    Conklin BR; Hsiao EC; Claeysen S; Dumuis A; Srinivasan S; Forsayeth JR; Guettier JM; Chang WC; Pei Y; McCarthy KD; Nissenson RA; Wess J; Bockaert J; Roth BL
    Nat Methods; 2008 Aug; 5(8):673-8. PubMed ID: 18668035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.